Valuation dashboard for MDxHealth S.A. (MDXH) with P/E N/A, P/B -2.89, EV/EBITDA -17.51 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool.
Analysis Summary
MDxHealth S.A. reported revenue of $107.9M in the most recent fiscal year, growing at a 5-year CAGR of 42.3%.
Trailing-twelve-month margins: gross margin 57.7%, operating margin -16.6%, net margin -32.2%.
At the current price of $0.65, MDXH has negative trailing earnings (P/E not meaningful) and an ROE of 402.97%. Market capitalisation stands at $33M.
Balance sheet quality for MDXH: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -2.89 |
| EV / EBITDA | -17.51 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-82.80 |
| vs Current Price | -12896.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MDXH | MDxHealth S.A. | $35M | 403.0% | ||
| 0R0H.L | Thermo Fisher Scientific Inc. | $244.6B | 35.47 | 4.45 | 12.6% |
| TMO | Thermo Fisher Scientific Inc. | $241.0B | 35.36 | 4.64 | 13.4% |
| 0R2B.L | Danaher Corporation | $150.1B | |||
| DHR | Danaher Corporation | $149.3B | 39.34 | 2.98 | 7.7% |
| NTRA | Natera, Inc. | $52.5B | 30.51 | -11.7% | |
| 0HAV.L | Agilent Technologies, Inc. | $47.8B | 95.79 | 6.15 | 6.4% |
| 0JDM.L | IQVIA Holdings Inc. | $45.7B |
Price
| Price | $0.65 |
| Market Cap | $33M |
| Exchange | NASDAQ |
| Country | BE |
Profitability
| Return on Equity | 402.97% |
| Return on Invested Capital | -12.74% |
| Return on Assets | -17.67% |
| Gross Margin | 57.68% |
| Operating Margin | -16.59% |
| Net Margin | -32.17% |
Related companies: ACRS · ASMB · IMRX · NEO · QTRX · SI · SNWV
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MDXH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks